News and Trends 22 Dec 2020 EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19 BioNTech and Pfizer’s Covid-19 vaccine, made from messenger RNA, has become the first of its kind to be approved by the EMA. The EMA has granted conditional approval to Comirnaty, a vaccine against Covid-19 developed by BioNTech and Pfizer. The approval comes weeks after the UK became the first country in the world to approve […] December 22, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2020 mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine The field of messenger RNA therapeutics is flying high as BioNTech and Pfizer conclude a phase III trial with their Covid-19 vaccine showing 95% effectiveness. The phase III trial recruited over 43,000 volunteers to gauge whether Covid-19 infections could be prevented by a vaccine made out of messenger RNA (mRNA). One group received two doses […] November 19, 2020 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2020 Pfizer-BioNTech Covid-19 Vaccine Shows Phase I Promise A vaccine made out of messenger RNA (mRNA), developed by the US pharmaceutical giant Pfizer and its German partner BioNTech, has produced antibodies against the Covid-19 pathogen in healthy volunteers. The results come from an interim analysis of an ongoing phase I clinical trial in 45 participants. So far, all test subjects who received two […] July 3, 2020 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2020 Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans Update (29/04/2020): A vaccine developed by the German company BioNTech and its big pharma partner Pfizer has become the first European mRNA vaccine for Covid-19 to enter human testing in a phase I/II trial. Since dosing began last week, twelve volunteers in Germany have been given the vaccine. The first part of the trial — […] April 29, 2020 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 30 Mar 2020 Could mRNA Vaccines Fulfill Their Potential Against Coronavirus? The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […] March 30, 2020 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2020 BioNTech Expands Cancer Portfolio With US Biotech Acquisition German cancer specialist BioNTech will acquire US T-cell therapy biotech Neon Therapeutics in a deal worth €60M, both to expand its cancer therapy pipeline and establish a US base. The deal is expected to complete in the second half of 2020, after which Neon will operate as a subsidiary of BioNTech. BioNTech has arguably scooped […] January 16, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2020 BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 18 Dec 2019 How BioNTech Navigates the Biotech Fundraising Maze BioNTech is on a mission to individualize cancer therapy by developing a range of different innovative therapies, a task that can be a rollercoaster ride, according to its Chief Business and Commercial Officer Sean Marett. It’s been an interesting year for the German biotech. In July the company raised one of the biggest ever European […] December 18, 2019 - 6 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 15 Oct 2019 Four New Technologies That Will Change Cancer Treatment New approaches to tame the immune system in the fight against cancer are getting us closer to a future where cancer becomes a curable disease. Personalized vaccines, cell therapy, gene editing and microbiome treatments are four technologies that will change the way cancer is treated. Curing cancer is certainly one of the big challenges of […] October 15, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2019 Update: BioNTech Files for €141M Nasdaq IPO BioNTech’s Nasdaq IPO has raised €141M ($155M), a lower sum than it initially anticipated. The timing of the IPO means it has likely been impacted by adverse market conditions, which are due to factors such as global manufacturing slowdowns and escalations in US and Chinese trade disputes. This same market volatility led several companies such […] October 10, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2019 BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […] July 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2019 European Biotech: The Insider View How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day. Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects […] July 7, 2019 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email